A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma (NCT03444948) | Clinical Trial Compass
SuspendedNot Applicable
A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma
Stopped: There was a voluntary recall from the Habib EUS RFA device manufacturer
Canada108 participantsStarted 2019-02-14
Plain-language summary
To assess if endoscopic ultrasound-guided radiofrequency ablation application in patients with inoperable pancreatic cancer confers survival benefit when compared to patients receiving standard medical care.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients above 18 years of age.
* A cytological / histological diagnosis of inoperable PDAC based on multidisciplinary review of cross-sectional imaging and cytology / histology results.
* Patients ought to be fit enough to be considered for the study (ECOG (Eastern Cooperative Oncology Group) performance status 0, 1 or 2)
* Patients who have commenced chemotherapy are not excluded from the study
* Patients capable of giving informed consent
* Negative blood pregnancy test for women of childbearing potential
* Willingness and ability to comply with all protocol requirements including scheduled visits, treatment plans, laboratory tests and other study procedures.
Exclusion Criteria:
* ECOG performance status 3 or 4
* Life expectancy less than 3 months (including liver metastases, carcinomatosis)
* Prior investigational drugs within the last 30 days
* Known infection with human immunodeficiency virus (HIV)